Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 15 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • duaklir genuair

    Duaklir Pressair

    Read More

    Duaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting muscarinic antagonist aclidinium.

    July 31, 2018
    Find out more
  • Nouriast

    Read More

    Nouriast (istradefylline; Kyowa Hakko Kirin) is the first, and so far, the only adenosine A2a receptor antagonist to be approved for the treatment of Parkinson’s disease. It acts to decrease overactivity of the indirect pathway of the motor circuit that is present in Parkinson’s disease patients with low dopamine levels.

    June 21, 2018
    Find out more
  • Wound Care: Tissue-Engineered Skin Replacements and Active Wound Repair Modulators

    $4,750.00

    This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the US, 5EU, Japan, and RoW markets for tissue-engineered skin replacements (epidermal, dermal, and multilayer equivalents, and amniotic tissue grafts) and active wound repair modulators (growth factors, gene therapy agents, and stem cells).

    September 23, 2020
    Find out more
  • Auryxia

    Read More

    Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease.

    January 11, 2018
    Find out more
  • Aramchol

    Read More

    Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the liver enzyme stearoyl-CoA desaturase 1 inhibitor (SCD1), and as a result fatty acid synthesis is reduced while fatty acid oxidation is increased. Additionally, Aramchol has hypocholesterolemic effects due to the upregulation of ATP-binding cassette transporter 1 (ABCA1). Ultimately, Aramchol causes incomplete SCD inhibition while also being anti-atherogenic.

    July 22, 2019
    Find out more
  • Visudyne

    Read More

    Visudyne (verteporfin; Valeant/Novartis) is a benzoporphyrin derivative photosensitizer developed for

    use in photodynamic therapy.

    April 4, 2016
    Find out more
  • Spain, Musculoskeletal Market Opportunities: Disease Incidence and Prevalence, and Surgical Procedure Volumes

    $1,995.00

    This report presents the disease incidence and prevalence and surgical procedure volumes for selected musculoskeletal disorders and procedures in Spain; incidence and prevalence figures are compared with those of the Benelux countries

    November 1, 2012
    Find out more
  • Company Analysis: AbbVie

    Read More

    PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.

    January 25, 2021
    Find out more
  • Ularitide

    Read More

    Ularitide’s (Cardiorentis) favorable results in its pivotal Phase III trial could be a key driver of uptake,

    especially as Natrecor (nesiritide; Johnson & Johnson), its major marketed competitor, failed to show

    added clinical value and benefit on survival.

    March 16, 2016
    Find out more
  • bempedoic acid franchise

    Bempedoic Acid Franchise

    Read More

    Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.

    November 20, 2019
    Find out more
  • Transcatheter Heart Valve Repair and Replacement Devices

    Transcatheter Heart Valve Repair and Replacement Devices

    $4,750.00

    In 2020, the global market for transcatheter heart valve management products, including transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve (TMV) repair products, totaled nearly $4.7bn, with TAVR products accounting for nearly 90% of sales.

    August 30, 2021
    Find out more
  • Xarelto

    Read More

    Xarelto (rivaroxaban; Bayer/Johnson & Johnson) is an oral anticoagulant indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in the US, EU, and Japan.

    March 15, 2018
    Find out more
  • Viekira Pak franchise

    Read More

    AbbVie’s Viekira Pak franchise comprises Viekira Pak ([paritaprevir + ritonavir + ombitasvir] + dasabuvir), Viekira XR ([paritaprevir + ritonavir + ombitasvir + dasabuvir]), and Technivie ([paritaprevir + ritonavir + ombitasvir]), which is branded as Viekirax outside the US market.

    November 6, 2017
    Find out more
  • Ninlaro

    Read More

    Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.

    August 9, 2018
    Find out more
  • Regenerative Medicine Landscape

    $2,995.00

    The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.

    July 21, 2017
    Find out more
Page 1 of 86
Page 1 of 86123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London, SW1P 1WG. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top